Robert Rottapel


Dr. Robert Rottapel is leader of OICR's Innovation in Target Validation Program, which aids in the development of novel diagnostic tests to identify the best set of agents to treat each cancer patient individually. For more information about Dr. Rottapel's research, please visit The Rottapel Lab .

Contact Information

Dr. Christine Misquitta

christine [dot] misquittaatutoronto [dot] ca

Telephone: 416-978-4019


2008 - Program Director, Innovation in Target Validation, Ontario Institute for Cancer Research (OICR).
2007 - Full Member, Institute of Medical Science, University of Toronto.
2006 - Professor, Department of Medicine, University of Toronto.
2005 - Division Head and Senior Scientist, Division of Stem Cell and Developmental Biology, Ontario Cancer Institute.
2000 - Rheumatologist, Department of Medicine, St. Michael's Hospital, Toronto.
2007 - 2012Amgen Chair for Cancer Research, University Health Network.

Research Output

  • Bakal CJ, Wu C, Finan D, Neale C, Rottapel R.
    A RhoGEF/dynein complex that activates Rho is required for spindle assembly
    • Proc Natl Acad Sci. USA. 2005; 5;102:9529-34
  • Ilangumaran S, Ramanathan S, La Rose J, Poussier P, Rottapel R
    Suppressor of cytokine signalling 1 regulates IL-15 receptor signalling in CD8+CD44 high memory T lymphocytes
    • J Immunol, 2003;171:2435-45
  • Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R
    Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region
    • Mol Cell Biol. 2003;9:3067-78
  • Okkenhaug K, Wu L, Ohashi P, Mak TW, Rottapel R
    A point mutation in CD28 distinguishes proliferative from survival signals
    • Nature Immunology. 2001;2:235
  • de Sepulveda P, Ilangumaran S, La Rose J, Rottapel R
    Socs1 precipitates the proteolytic destruction of the hematopoietic specific guanine nucleotide exchange factor Vav
    • Journal of Biological Chemistry. 2000; 275:14005-14008